Related Experiment Videos

Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis

A C Carr1, M C Myzak, R Stocker

  • 1Linus Pauling Institute, Oregon State University, 571 Weniger Hall, Corvallis, OR 97331-6512, USA. anitra.carr@orst.edu

FEBS Letters
|January 11, 2001
PubMed

Insights

Myeloperoxidase (MPO) binds to low-density lipoprotein (LDL), potentially promoting atherosclerosis. This interaction may enhance LDL oxidation and hinder antioxidant activity, contributing to foam cell formation.

Area of Science:

  • Biochemistry
  • Cardiovascular Research
  • Cell Biology

Background:

  • Myeloperoxidase (MPO) is an enzyme released by phagocytes.
  • MPO modifies low-density lipoprotein (LDL), leading to foam cell formation, a key feature of atherosclerosis.
  • MPO's interaction with various cell types is known, but its binding to LDL was uninvestigated.

Purpose of the Study:

  • To investigate the binding of Myeloperoxidase (MPO) to low-density lipoprotein (LDL).
  • To understand the implications of MPO-LDL interaction in the context of atherosclerosis.

Main Methods:

  • Co-precipitation of MPO and LDL using phosphotungstate or isopropanol.
  • Confirmation of MPO-LDL association via native gel electrophoresis.
  • Analysis of MPO precipitation with lipoproteins in whole plasma and lipoprotein-deficient plasma.

Main Results:

  • MPO co-precipitated with LDL, retaining its catalytic activity.
  • MPO associated with apolipoprotein B-100-containing lipoproteins in plasma.
  • LDL addition to lipoprotein-deficient plasma showed a dose-dependent increase in MPO precipitation.

Conclusions:

  • Myeloperoxidase (MPO) directly binds to low-density lipoprotein (LDL).
  • This binding may enhance site-directed oxidation of LDL.
  • The MPO-LDL interaction could potentially limit antioxidant scavenging of reactive oxygen species, promoting atherosclerotic lesion development.

Related Concept Videos